title: Correlates of the preoperative level of CA125 at presentation of ovarian cancer.
abstract: OBJECTIVE
  CA125 at presentation of ovarian cancer carries important prognostic significance; but, other than tumor characteristics, little is known about factors that influence CA125 levels. We examined the effect of epidemiologic variables and tumor features on CA125 at diagnosis and their effects on survival.
  
  
  METHODS
  CA125 levels before treatment, tumor features, and questionnaire data from 805 women with ovarian cancer receiving care at Partners Hospitals were recorded. CA125 values were log-normalized and generalized linear, logistic, or Cox proportional hazards models used to identify predictors of CA125 and influence on survival in the subset of women with invasive, nonmucinous tumors.
  
  
  RESULTS
  The importance of histology, grade, stage, laterality, and presence of ascites on CA125 level was confirmed. For nonmucinous invasive cancers, Jewish ethnicity, parity, prior breast cancer, and family history of breast or ovarian cancer predicted higher CA125, and greater body mass index (BMI), recurrent yeast infections, colitis, and appendectomy predicted lower CA125. A quadratic model best described the relationship between CA125 and age with lower levels in youngest and oldest women. In multivariate modeling, stage, ascites, and prior breast cancer were the strongest predictors of high CA125 and appendectomy and yeast infections strongest predictors of low CA125. A model with these variables plus CA125 revealed high CA125 remains a predictor of poorer survival.
  
  
  CONCLUSIONS
  Ovarian tumor features and presence of ascites are key determinants of CA125 at diagnosis, but epidemiologic features such as BMI, parity, prior breast cancer, and history of inflammatory conditions of the genitourinary or gastrointestinal tracts may also play a role.
authors.affiliation: Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, MA, USA. dcramer@partners.org
authors.forename: Daniel W
authors.initials: DW
authors.lastname: Cramer
authors.forename: Allison F
authors.initials: AF
authors.lastname: Vitonis
authors.forename: William R
authors.initials: WR
authors.lastname: Welch
authors.forename: Kathryn L
authors.initials: KL
authors.lastname: Terry
authors.forename: Annekathryn
authors.initials: A
authors.lastname: Goodman
authors.forename: Bo R
authors.initials: BR
authors.lastname: Rueda
authors.forename: Ross S
authors.initials: RS
authors.lastname: Berkowitz
mesh_terms: D018394:CA-125 Antigen / Q000378:metabolism*; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D016015:Logistic Models; D008404:Massachusetts / Q000453:epidemiology; D008875:Middle Aged; D009513:New Hampshire / Q000453:epidemiology; D010051:Ovarian Neoplasms / Q000453:epidemiology / Q000378:metabolism*; D011300:Preoperative Care; D011379:Prognosis; D016016:Proportional Hazards Models
chemical_list: D018394:CA-125 Antigen